From bright ideas to lives saved

Steve Davis
President and CEO, PATH
Share:
A hand holding a looking glass by a lake
Crowdsource Innovation
Get involved with our crowdsourced digital platform to deliver impact at scale

We have less than two years to hold ourselves accountable to worldwide health and development goals set for 2015. As leaders from the private, public and nonprofit sectors convene at Davos, we must ask ourselves, “How can we do better?”

Collectively, we have made significant strides in improving health. Fewer young children are dying of preventable diseases – yet 18,000 children still die each day. We have nearly halved the number of women dying from complications due to pregnancy or childbirth – yet still, one woman dies every minute.

In the last decade, the global community has invested in one of the largest pipelines of life-saving technologies the world has ever seen. At PATH alone, the leading innovator in global health, we have more than 200 technologies in our pipeline, and we are also working with emerging-country vaccine suppliers from China and India to accelerate their innovations. From rapid diagnostic tests for malaria to affordable devices to prevent postpartum hemorrhage, many solutions exist, and others are on the horizon.

Yet, too often, the bright ideas fail to reach the people who need them most. One key approach – one that’s being discussed fervently this week at Davos – is creating partnerships that transcend sectors. To transform ideas into solutions that help millions of people, we need intentional collaboration between strange bedfellows who bring different, but complementary, resources.

In the quest for a stable supply of malaria treatments, for example, PATH gathered experts from academia, biotechnology and the pharmaceutical industry to develop the world’s first semisynthetic form of artemisinin for malaria treatment. Together, over nine years, we moved the product from an idea to large-scale industrial production. Our partner Sanofi is currently on track to produce enough artemisinin for approximately 150 million treatments a year. Consider the impact this will have on a disease that kills 660,000 people each year and costs Africa an estimated US$ 12 billion in lost productivity.

As conversations this week reflect, the expanded use of technology and increased civic participation around the world add exciting promise to these intentional collaborations by bringing fresh voices and new approaches to old challenges.

We have an unprecedented opportunity to solve long-standing problems by partnering with new allies, including developing countries who offer new sources for innovative solutions. So what can we do? Let’s connect the dots between the leaders convening here this week and the sectors they represent to make sure we seize this moment.

Author: Steve Davis is president and chief executive officer of PATH. 

Image: A health worker marks the finger of a child after administering a vaccine in India. REUTERS/Ajay Verma 

Don't miss any update on this topic

Create a free account and access your personalized content collection with our latest publications and analyses.

Sign up for free

License and Republishing

World Economic Forum articles may be republished in accordance with the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Public License, and in accordance with our Terms of Use.

The views expressed in this article are those of the author alone and not the World Economic Forum.

Share:
World Economic Forum logo
Global Agenda

The Agenda Weekly

A weekly update of the most important issues driving the global agenda

Subscribe today

You can unsubscribe at any time using the link in our emails. For more details, review our privacy policy.

About Us

Events

Media

Partners & Members

  • Join Us

Language Editions

Privacy Policy & Terms of Service

© 2024 World Economic Forum